| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA2349283
Max Phase: Preclinical
Molecular Formula: C29H20FN3S2
Molecular Weight: 493.63
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: N#Cc1ccccc1-c1ccc(CSc2nc(SCc3ccc(F)cc3)nc3ccccc23)cc1
Standard InChI: InChI=1S/C29H20FN3S2/c30-24-15-11-21(12-16-24)19-35-29-32-27-8-4-3-7-26(27)28(33-29)34-18-20-9-13-22(14-10-20)25-6-2-1-5-23(25)17-31/h1-16H,18-19H2
Standard InChI Key: TYFUYKLAIDPONX-UHFFFAOYSA-N
Associated Targets(Human)
Phosphodiesterase 7 77 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 493.63 | Molecular Weight (Monoisotopic): 493.1083 | AlogP: 7.89 | #Rotatable Bonds: 7 |
| Polar Surface Area: 49.57 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 0 |
| #RO5 Violations: 1 | HBA (Lipinski): 3 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: | CX Basic pKa: 1.89 | CX LogP: 8.84 | CX LogD: 8.84 |
| Aromatic Rings: 5 | Heavy Atoms: 35 | QED Weighted: 0.13 | Np Likeness Score: -1.50 |
References
| 1. Sánchez AI, Martínez-Barrasa V, Burgos C, Vaquero JJ, Alvarez-Builla J, Terricabras E, Segarra V.. (2013) Synthesis and evaluation of quinazoline derivatives as phosphodiesterase 7 inhibitors., 21 (8): [PMID:23454131] [10.1016/j.bmc.2013.01.067] |
Source
Source(1):